Schindlbeck, Katharina A.
Gupta, Deepak K.
Tang, Chris C.
O’Shea, Sarah A.
Poston, Kathleen L.
Choi, Yoon Young
Dhawan, Vijay
Vonsattel, Jean-Paul
Fahn, Stanley
Eidelberg, David http://orcid.org/0000-0002-0854-864X
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (P50 NS 071675)
Article History
Received: 3 December 2020
Accepted: 7 March 2021
First Online: 10 April 2021
Declarations
:
: Ethical permission for this study was obtained from the Institutional Review Board of the participating institutions (Columbia University and Northwell Health).
: A waiver of consent was granted for this study.
: K.L.P. has received clinical trial grants from Sanofi and AstraZeneca (unrelated to manuscript) and consulting fees from Allergan and CuraSen (unrelated to manuscript). D.E. serves on the scientific advisory boards of and has received fees from The Michael J. Fox Foundation for Parkinson’s Research and Ovid Therapeutics (unrelated to manuscript); receives consulting fees from MeiraGTx (unrelated to manuscript); has received grants from NIH (NINDS, NIAID) (unrelated to manuscript); and is the coinventor of patents re: Markers for use in screening patients for nervous system dysfunction and a method and apparatus for using same, without financial gain. All other authors disclose no relevant conflict of interest.
: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the National Institute of Neurological Disorders and Stroke.